hepat
c
lifethreaten
widespread
viral
infect
viru
initi
infect
liver
cell
though
remain
asymptomat
extend
period
invis
constitut
epidemiolog
challeng
patient
diagnos
hepat
c
come
two
pool
recent
infect
latestag
asymptomat
initi
symptom
fever
fatigu
nausea
liver
tender
mislead
toler
patient
sever
year
bloodborn
infect
viru
activ
replic
caus
complic
start
liver
scar
fibrosi
follow
cirrhosi
eventu
liver
failur
carcinoma
awar
hepat
c
health
problem
forc
effort
combat
spread
hepat
c
viru
hcv
healthcar
set
led
signific
declin
new
hepat
c
case
howev
annual
death
toll
complic
diseas
remain
high
due
describ
uniqu
clinic
vs
epidem
profil
chronic
hepat
c
estim
million
peopl
global
current
infect
hcv
constitut
major
health
problem
death
rate
hcv
complic
surpass
hiv
hepat
crelat
death
exceed
tuberculosi
malaria
combin
interferon
pegyl
interferon
ribavirin
effect
avail
therapi
longterm
efficaci
low
identif
hepat
c
earli
prompt
intens
research
led
introduct
new
class
direct
antivir
agent
daa
daa
revolution
treatment
hepat
c
succeed
control
global
crisi
epidem
describ
third
millennium
challeng
recent
combin
daa
becom
effect
way
cover
hepat
c
infect
differ
genotyp
nonetheless
accord
world
health
organ
sever
remain
challeng
must
met
erad
hcv
access
treatment
econom
challeng
area
must
increas
emerg
drug
resist
expect
problem
even
combin
therapi
efficaci
broader
sector
hcv
patient
elderli
impair
kidney
liver
patient
must
improv
thu
clear
need
identifi
new
approach
inhibit
viral
target
increas
daa
arsen
hcv
genom
positivesens
singlestrand
rna
viru
belong
flavivirida
translat
viru
genom
mainli
correspond
structur
nonstructur
protein
nonstructur
ns
protein
includ
compris
factor
essenti
matur
replic
viru
dualli
function
proteas
ntermin
domain
rna
helicas
ctermin
domain
activ
proteas
catalyz
process
viral
proteom
function
protein
cleav
junction
proper
fold
indispens
proteas
activ
occur
bind
amino
acid
peptid
multipl
function
requir
activ
also
import
integr
host
cell
endoplasm
reticulum
neutral
host
cell
immun
respons
proteas
first
foremost
target
viral
protein
daa
bind
substrat
site
interfer
bind
site
hand
evalu
thoroughli
mechan
alloster
inhibit
protein
especi
druglik
peptidomimet
articl
present
compound
design
compet
replac
bind
site
lead
inhibit
ntermin
intercal
first
residu
ntermin
associ
induc
proper
conform
apoenzym
increas
proteolyt
activ
time
accumul
evid
establish
central
region
suffici
activ
proteas
throughout
paper
prime
mark
appli
differenti
residu
apoenzym
also
confirm
laboratori
other
certain
mutant
bind
site
inhibit
proteas
function
report
first
crystal
structur
kim
cowork
state
contact
surfac
quit
extens
provid
anoth
possibl
site
design
antihcv
chemotherapeut
agent
howev
subsequ
research
focus
mere
discoveri
substrat
site
inhibitor
mention
site
inhibitor
rare
report
describ
hypothet
approach
accordingli
decid
pursu
concept
design
peptidomimet
bind
replac
proteas
domain
first
step
de
novo
design
peptidomimet
inspect
crystal
structur
complex
protein
data
bank
pdb
code
notic
form
mostli
extend
except
turn
kink
featur
nearli
planar
area
planar
kink
compos
one
eclips
ci
bond
dihedr
angl
neg
sign
denot
deviat
opposit
side
side
chain
four
near
perfect
planar
tran
bond
span
figur
torsion
tabl
supplementari
materi
tabl
ci
bond
larg
depend
presenc
allow
lessen
steric
conflict
side
chain
interestingli
glycin
turn
conserv
crystal
structur
hcv
proteas
protein
data
bank
pdb
deposit
date
regardless
genotyp
sequenc
construct
use
fuse
nonfus
see
supplementari
materi
figur
accordingli
postul
imidazol
nucleu
append
two
amid
group
mimic
planar
region
dock
experi
manual
visual
guid
method
suggest
nucleu
occupi
planar
region
keep
key
interact
place
without
pose
signific
steric
conflict
figur
particular
imidazol
act
hydrogen
bond
donor
backbon
carbonyl
locat
also
made
hydrogen
bond
co
group
design
scaffold
carbonyl
group
occupi
planar
area
rest
previou
studi
side
chain
deem
unnecessari
function
therefor
could
safe
replac
intend
amid
carbonyl
pocket
accommod
hydrophob
side
chain
sought
opportun
increas
bind
potenc
compound
context
probe
hydrophob
pocket
decid
synthes
compound
differ
hydrophob
substitu
amid
group
imidazol
carboxamid
occupi
posit
amid
bond
conserv
hydrogen
bond
locat
within
sheet
agmantyl
substitu
occupi
posit
side
chain
addit
bifurc
hydrogen
bond
backbon
carbonyl
nh
group
compens
hydrogen
bond
accept
core
figur
final
moc
compound
synthes
use
report
chemistri
illustr
synthet
scheme
moc
refer
project
code
therefor
final
compound
code
necessarili
sequenti
start
start
cyanoform
acid
ethyl
ester
nitril
group
convert
nhydroxyamidino
deriv
nucleophil
addit
hydroxylamin
pivot
imidazol
intermedi
prepar
thermal
microwav
irradi
mwi
induc
cyclocondens
tertbutyl
propiol
compound
featur
desir
imidazol
nucleu
contain
two
differ
ester
group
ethyl
alkali
labil
tbutyl
acid
labil
therefor
trifluoroacet
acid
tfa
treatment
could
select
hydrolyz
tertbutyl
ester
acid
carboxyl
acid
react
select
amin
substitu
catalysi
carbodiimid
edci
hydrat
hobt
give
intermedi
ethyl
ester
hydrolyz
lithium
salt
use
lioh
final
compound
obtain
coupl
desir
amin
effect
propylphosphon
anhydrid
previou
amid
coupl
step
methylamino
provid
npentyl
nhexyl
respect
intermedi
dibocagmantyl
boc
tertbutoxycarbonyl
result
intermedi
directli
subject
acid
condit
boc
deprotect
obtain
moc
final
compound
studi
bind
moc
compound
differenti
static
light
scatter
dsl
domain
stabil
upon
bind
measur
monitor
denatur
protein
aggreg
upon
increas
temperatur
gradual
increment
nm
ligand
bind
protein
increas
protein
aggreg
temperatur
tagg
dsl
provid
advantag
labelfre
bind
assay
techniqu
ligand
protein
use
assess
rel
bind
affin
ligand
valu
occur
upon
bind
moc
compound
measur
compar
posit
control
posit
control
demonstr
signific
affin
toward
figur
assay
measur
potenc
synthet
peptidomimet
affect
bind
label
test
moc
compound
bind
affin
fluorescein
isothiocyan
first
determin
see
supplementari
materi
figur
base
previou
work
particular
protein
batch
optim
ratio
use
fa
affin
test
calcul
compound
effici
compet
expect
decreas
fluoresc
emit
mixtur
result
show
strongest
competit
potenc
assay
show
half
maxim
inhibitori
concentr
tabl
figur
follow
also
show
moder
inhibit
bind
competit
compound
demonstr
weaker
affin
competit
valu
exert
inhibit
bind
select
qualit
test
inhibit
proteas
activ
experi
carri
use
hcv
proteas
assay
kit
assay
measur
recov
fluoresc
emit
upon
cleavag
label
peptid
substrat
repres
junction
consid
without
almost
thousandtim
less
catalyt
method
modifi
suit
purpos
alloster
inhibit
assay
instanc
use
larg
amount
free
protein
smaller
concentr
show
measur
catalyt
activ
absenc
cofactor
addit
amount
result
complet
loss
catalyt
activ
posit
control
equimolar
mixtur
equimolar
caus
increas
catalyt
activ
enzym
figur
far
less
report
valu
possibl
due
larg
amount
protein
use
order
ration
differ
bind
affin
repres
activ
inact
compound
respect
perform
molecular
dynam
md
simul
ns
manual
dock
compound
place
intend
pocket
follow
energi
relax
md
simul
tri
disrupt
nonbond
interact
ligand
bind
site
residu
appli
energi
snapshot
result
conform
excit
follow
relax
equilibr
occur
equilibr
system
determin
plot
protein
root
mean
squar
deviat
plrmsd
vs
simul
time
certain
interact
stay
uninterrupt
equilibrium
reach
indic
higher
possibl
occurr
postul
bind
mode
first
md
control
experi
perform
crystal
structur
pdb
code
expect
viral
complex
maintain
high
degre
stabil
low
residu
fluctuat
simul
period
see
supplementari
materi
figur
md
simul
model
demonstr
three
import
featur
ligand
resid
entir
simul
period
ns
within
boundari
presum
bind
region
locat
b
imidazol
nucleu
low
interact
fluctuat
c
nhexyl
side
chain
stay
deep
hydrophob
pocket
accommod
side
chain
video
illustr
avail
part
supplementari
materi
monitor
plrmsd
simul
indic
conform
fluctuat
protein
backbon
atom
equilibr
ns
statu
maintain
toward
end
simul
period
figur
meanwhil
ligand
equilibr
ns
protein
ligand
clearli
show
least
fluctuat
ns
simul
end
ns
indic
complex
reach
stabil
bind
mode
accordingli
look
care
conform
behavior
crucial
core
three
phase
ligand
conform
dynam
gener
imidazol
nucleu
especi
nh
posit
show
low
fluctuat
figur
first
phase
ns
notic
core
maintain
two
hydrogen
bond
presum
situat
accord
design
hypothesi
describ
figur
around
ns
imidazol
ring
start
detect
interact
residu
within
opposit
locat
peripheri
protein
figur
ns
settl
embrac
backbon
via
two
hydrogen
bond
interact
process
lost
contact
major
flip
imidazol
commit
show
low
fluctuat
toward
end
simul
figur
behavior
hydrophob
substitu
attach
carboxamid
critic
issu
model
moieti
compound
differ
activ
inact
nhexyl
group
stay
deep
hydrophob
pocket
although
show
strong
commit
certain
amino
acid
activ
site
regard
interact
residu
nhexyl
side
chain
hydrophob
nhexyl
show
low
rmsf
compar
polar
substitu
figur
md
simul
result
consist
lack
bind
inact
contain
bulkier
hydrophob
substitu
end
cyclohexyl
group
simul
time
progress
cyclohexyl
group
forc
outsid
hydrophob
pocket
fact
whole
molecul
left
bind
region
locat
imidazol
made
minor
contact
ligand
clearli
pop
outsid
settl
near
protein
surfac
figur
movement
indic
lack
affin
bind
pocket
last
point
obtain
md
studi
role
polar
agmantyl
group
group
serv
polar
head
suitabl
microenviron
around
bound
group
altern
interact
peripheri
simul
solvent
odd
observ
show
similar
behavior
report
crystal
structur
see
supplementari
materi
figur
introduct
daa
combin
allow
broaden
efficaci
hcv
treatment
pangenotyp
orbit
combin
made
possibl
identif
target
viral
proteom
instanc
combin
sofosbuvir
inhibitor
velpatasvir
inhibitor
voxilaprevir
proteas
inhibitor
cover
hcv
genotyp
truli
motiv
inclus
competitor
lessstudi
target
toward
potenti
embolden
arsen
daa
combin
howev
extens
literatur
search
could
find
preced
design
andor
screen
smallmolecul
peptid
mimic
addit
advantag
target
vital
compon
versatil
small
peptid
commonli
express
entir
flavivirida
famili
virus
besid
hcv
includ
danger
pathogen
virus
zika
west
nile
dengu
virus
therefor
effect
peptidomimet
may
constitut
possibl
gener
approach
combat
flavivirida
approach
peptidomimet
design
depend
simpl
observ
conform
bound
relev
residu
involv
design
virtual
design
appear
satisfactorili
reproduc
stereochemistri
featur
inde
could
experiment
confirm
compound
display
bind
affin
toward
abund
type
middl
east
work
allow
quantifi
bind
affin
design
moc
compound
fa
competit
assay
confirm
bind
bind
site
dsl
fa
assay
gener
agreement
show
exert
good
affin
toward
structur
three
compound
contain
npentyl
homologu
nhexyl
posit
larger
hydrophob
group
posit
lower
bind
affin
dsl
fa
test
indic
pocket
limit
bulk
toler
regard
posit
screen
compound
contain
agmantyl
group
except
agmantyl
group
chosen
mimic
addit
agmantyl
moieti
hypothes
act
hook
group
direct
imidazol
scaffold
intend
posit
synthes
append
two
differ
polar
group
posit
encompass
glycinyl
moieti
backbon
mimic
compar
agmantyl
analogu
produc
higher
increas
tagg
show
lower
competit
potenc
fa
assay
indic
presenc
side
chain
may
replac
anoth
polar
group
relationship
sar
featur
import
futur
research
toward
optim
peptidomimet
remov
guanidinyl
less
desir
group
drug
discoveri
due
high
ioniz
poor
pharmacokinet
present
radic
differ
variant
side
chain
group
compound
show
much
weaker
bind
test
indic
success
peptid
mimic
includ
close
mimic
amino
acid
featur
glycinyl
agmantyl
homologu
exert
confirm
bind
activ
reveal
dsl
fa
test
show
thermal
stabil
compar
natur
cofactor
fa
assay
demonstr
highest
abil
displac
bind
among
test
compound
moreov
vitro
proteas
assay
show
inhibit
form
inact
complex
howev
test
could
develop
quantit
applic
due
week
catalyt
activ
vitro
condit
md
simul
conduct
cours
studi
use
valid
design
hypothesi
explain
bind
potenc
differ
repres
activ
inact
compound
respect
remark
stay
region
nhexyl
group
complet
buri
deep
hydrophob
pocket
entir
md
simul
time
question
frequent
come
mind
conform
effect
occur
consequ
bind
peptidomimet
eg
question
secondari
import
anyway
prevent
bind
nonpeptid
mimic
lead
inabl
perform
catalyt
function
collect
work
introduc
new
strategi
interfer
proteas
activ
use
compound
repres
nonpeptid
mimic
fragment
must
acknowledg
compound
repres
four
amino
acid
core
cover
limit
region
bind
site
consid
promis
activ
limit
molecular
weight
mw
result
demonstr
bind
good
target
discoveri
newer
gener
daa
work
consid
bridg
peptid
nonpeptid
mimic
expans
upon
lead
pave
way
futur
discoveri
competitor
clinic
candid
water
mlmmol
ad
dropwis
period
h
stir
mixtur
ethyl
cyanoform
equiv
g
mmol
hydroxylamin
hydrochlorid
equiv
g
mmol
sodium
carbon
equiv
g
mmol
ethanol
ml
room
temperatur
rt
upon
complet
reaction
quench
solvent
remov
vacuum
result
residu
extract
dichloromethan
combin
organ
layer
wash
brine
dri
filter
concentr
afford
white
solid
intermedi
z
hydroxyimino
acet
intermedi
recrystal
chloroform
nheptan
afford
white
crystal
g
mp
use
without
purif
next
step
intermedi
equiv
g
mmol
tertbutyl
propiol
equiv
g
mmol
equiv
ml
mmol
ad
toluen
ml
result
solut
microwaveirradi
min
w
heat
ramp
min
solvent
evapor
final
product
purifi
crystal
ethyl
acet
etoac
hexan
obtain
mg
mp
nmr
mhz
dmso
ppm
br
h
h
q
j
hz
h
h
j
hz
h
nmr
mhz
ir
ftir
esi
rt
min
mz
h
solut
equiv
g
mmol
tfa
ml
dichloromethan
dcm
ml
stir
h
room
temperatur
rt
solvent
evapor
vacuum
remain
residu
treat
meoh
ml
filter
give
yellow
solid
g
mp
decompos
nmr
mhz
ppm
br
h
br
h
q
j
hz
j
hz
esi
rt
min
mz
h
inert
atmospher
carboxyl
acid
equiv
mmol
dissolv
dri
thf
ml
edci
equiv
g
mmol
hobt
equiv
mg
mmol
diisopropylethylamin
dipea
equiv
ml
mmol
amin
equiv
mmol
ad
indic
order
mixtur
stir
rt
h
heat
h
edci
equiv
g
mmol
hobt
equiv
g
mmol
dipea
equiv
ml
mmol
ad
mixtur
complet
mixtur
purifi
column
chromatographi
use
gradient
elut
etoac
cyclohexan
ethyl
methylamino
carbamoyl
yield
mp
nmr
mhz
ppm
br
q
j
hz
j
hz
j
hz
j
hz
esi
rt
min
mz
h
ethyl
carbamoyl
intermedi
obtain
oili
substanc
yield
nmr
mhz
ppm
br
h
j
hz
j
hz
j
hz
j
hz
q
j
hz
j
hz
esi
rt
min
mz
h
ethyl
e
tertbutoxycarbonyl
guanidino
butyl
carbamoyl
solut
equiv
g
mmol
thf
ml
ad
solut
tertbutoxycarbonyl
equiv
mg
mmol
thf
mlmmol
within
h
solut
stir
room
temperatur
h
complet
solvent
remov
vacuum
product
purifi
column
chromatographi
silica
gel
use
mixtur
dcmmeoh
give
amino
carboxyamino
methylen
carbam
acid
ditertbutyl
ester
g
nmr
mhz
ppm
br
h
br
h
h
j
hz
h
h
h
h
esi
rt
min
mz
h
produc
amin
amino
carboxyamino
methylen
carbam
acid
ditertbutyl
ester
react
carboxyl
acid
accord
gener
procedur
amid
coupl
describ
section
intermedi
collect
oili
substanc
yield
g
compound
use
next
step
day
without
character
inert
atmospher
lithium
salt
mg
mmol
dissolv
dri
thf
ml
mlmmol
propanephosphon
acid
anhydrid
ml
solut
thf
equiv
npentylamin
ml
equiv
ad
mixtur
stir
room
temperatur
h
h
addit
equiv
ad
mixtur
upon
reaction
complet
solvent
evapor
vacuum
residu
purifi
silica
gel
column
gradient
elut
meoh
give
g
white
solid
mp
nmr
mhz
ppm
j
hz
nmr
mhz
ppm
esi
rt
min
mz
h
compound
prepar
accord
procedur
describ
prepar
start
nhexylamin
obtain
oili
substanc
yield
nmr
mhz
ppm
j
hz
j
hz
j
hz
br
j
hz
nmr
mhz
ppm
esi
rt
min
mz
h
lithium
carboxyl
salt
react
npentylamin
accord
procedur
describ
prepar
collect
intermedi
tertbutoxycarbonyl
guanidino
butyl
carbamoyl
npentyl
subject
deprotect
reaction
remov
boc
group
thu
dissolv
dri
dcm
mlmmol
hydrochlor
acid
solut
mlmmol
ad
reaction
mixtur
stir
rt
h
complet
reaction
mixtur
concentr
dri
vacuum
purifi
use
prepar
hplc
furnish
mp
nmr
mhz
ppm
br
br
br
nmr
mhz
ppm
esi
rt
min
mz
h
compound
prepar
accord
procedur
describ
synthesi
product
obtain
yellowish
oili
substanc
nmr
mhz
ppm
br
j
hz
br
nmr
mhz
ppm
esi
rt
min
mz
h
compound
prepar
accord
procedur
describ
synthesi
product
obtain
yellowish
oili
substanc
nmr
mhz
ppm
br
br
br
nmr
mhz
ppm
esi
rt
min
mz
h
compound
prepar
accord
procedur
describ
synthesi
product
obtain
yellowish
oili
substanc
nmr
mhz
ppm
j
hz
nmr
mhz
ppm
esi
rt
min
mz
h
compound
prepar
accord
procedur
describ
synthesi
product
obtain
offwhit
solid
mp
nmr
mhz
ppm
j
hz
j
hz
j
hz
br
br
br
nmr
mhz
ppm
esi
rt
min
mz
h
compound
prepar
accord
procedur
describ
synthesi
product
obtain
offwhit
solid
mp
nmr
mhz
ppm
j
hz
j
hz
br
quin
j
hz
nmr
mhz
ppm
esi
rt
min
mz
h
compound
prepar
accord
procedur
describ
synthesi
product
obtain
oili
substanc
nmr
mhz
ppm
br
j
hz
nmr
mhz
ppm
esi
rt
min
mz
h
compound
prepar
accord
procedur
describ
synthesi
product
obtain
solid
mp
nmr
mhz
ppm
nmr
mhz
ppm
esi
rt
min
mz
h
compound
prepar
accord
procedur
describ
synthesi
product
obtain
offwhit
oili
substanc
nmr
mhz
ppm
br
td
j
hz
nmr
mhz
ppm
esi
rt
min
mz
h
synthet
gene
code
hcv
domain
genotyp
abund
hcv
saudi
arabia
egypt
synthes
genscript
hong
kong
china
nucleotid
sequenc
optim
escherichia
coli
codon
usag
synthet
gene
clone
fragment
express
vector
obtain
construct
sequenc
confirm
ident
frame
express
construct
access
hcv
genotyp
common
genotyp
saudi
arabia
aa
le
fe
iq
lq
cs
aa
g
svvivgrvnl
sgdtayaqqt
rgeestqet
qtgrdtnenc
gevqvlstat
qsflgtavng
vmwtvyhgag
sktisgpkgp
vnqmytnvdq
dlvgwpsppg
vksltpctcg
asdlylvtrh
advvpvrrrg
dtrgallspr
pistlkgssg
gpllcpmgha
aglfraavst
rgvakavdfv
pveslett
mrsp
fusion
protein
express
proteas
domain
aa
plu
ntermin
tag
ctermin
tag
mark
uppercas
asmtggqqmg
apitayaqqt
rglfstivt
ltgrdtnenc
gevqvlstat
qsflgtavng
vmwtvyhgag
sktisgpkgp
vnqmytnvdq
dlvgwpsppg
vksltpctcg
asdlylvtrh
advvpvrrrg
dtrgallspr
pistlkgssg
gpllcpmgha
aglfraavct
rgvakavdfv
pveslettmr
sgshhhhhh
sequenc
express
sequenc
domain
genotyp
express
e
coli
rosett
plyss
accord
standard
protocol
therefor
synthet
gene
domain
subclon
express
vector
ml
bacteri
cultur
luria
broth
lb
medium
grown
overnight
use
inocul
l
lb
l
ferment
flask
new
brunswick
scientif
co
enfield
ct
usa
media
supplement
ampicillin
cultur
grown
reach
cool
mm
iptg
ad
express
overnight
follow
harvest
cell
produc
protein
purifi
use
equilibr
nickel
nitrilotriacet
acid
ninta
bead
without
remov
polyhistidin
tag
process
cell
first
resuspend
ml
buffer
mm
acid
hepe
nacl
glycerol
mm
ph
lysozym
ad
mgml
follow
proteas
inhibitor
cocktail
tablet
suspens
sonic
cell
lysat
centrifug
collect
clear
supernat
contain
desir
protein
protein
purifi
use
preequilibr
ninta
bead
qiagen
germantown
md
usa
bead
wash
buffer
mm
hepe
nacl
glycerol
mm
mm
imidazol
ph
elut
anoth
buffer
mm
hepe
nacl
glycerol
mm
mm
imidazol
ph
fraction
collect
concentr
use
amicon
mwco
centrifug
devic
merck
kgaa
darmstadt
germani
protein
puriti
niaffin
purif
step
less
puriti
estim
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
suffici
perform
investig
studi
protein
stabl
sever
hour
test
condit
concentr
final
concentr
measur
use
nanoscal
spectrophotomet
need
purif
protein
accomplish
superdex
column
ge
healthcar
chicago
il
usa
equilibr
mm
hepe
mm
ddt
mm
nacl
ph
run
rate
mlmin
follow
sdspage
puriti
estim
cofactor
fluoresc
fluorescein
isothiocyan
purchas
genscript
hong
kong
china
structur
ident
hcv
genotyp
two
lysin
residu
ad
n
ctermini
thu
structur
use
studi
studi
bind
mutant
dsl
use
harbing
biotechnolog
engin
corpor
toronto
canada
method
assess
protein
stabil
monitor
aggreg
format
use
control
gradual
elev
temperatur
domain
stabil
upon
bind
measur
monitor
denatur
protein
aggreg
upon
increas
temperatur
increment
nm
tagg
valu
calcul
automat
raw
data
use
softwar
experi
repeat
three
time
use
batch
protein
domain
alon
mix
equimolar
equival
test
moc
deriv
ad
bind
buffer
mm
hepe
mm
dtt
mm
nacl
ph
final
volum
mixtur
incub
room
temperatur
gentl
shake
h
afterward
mixtur
transfer
clear
bottom
nunc
plate
cover
paraffin
oil
minim
evapor
protein
aggreg
monitor
track
chang
scatter
light
detect
charg
coupl
devic
ccd
camera
snapshot
imag
plate
taken
everi
pixel
intens
preselect
region
well
integr
use
imag
analysi
softwar
gener
valu
repres
total
amount
scatter
light
region
intens
plot
temperatur
sampl
well
fit
obtain
aggreg
temperatur
tagg
aggreg
monitor
analyz
assess
effect
synthet
analogu
stabil
indic
bind
experi
repeat
three
time
statist
analysi
perform
use
graphpad
prism
v
v
softwar
plate
ad
place
bind
buffer
mm
hepe
mm
dtt
mm
nacl
ph
mixtur
calcul
affin
constant
concentr
serial
dilut
moc
compound
dissolv
dmso
bind
buffer
dilut
start
mix
gentli
min
dark
place
fluoresc
measur
excitationemiss
wavelength
nm
competit
calcul
accord
recommend
equat
embed
graphpad
prism
v
softwar
assay
perform
use
hcv
proteas
assay
kit
fluorometr
anaspec
fremont
ca
usa
accord
modifi
procedur
suit
purpos
determin
alloster
inhibit
mix
min
afterward
fluoresc
reson
energi
transfer
fret
peptid
ad
instruct
assay
kit
manual
sequenc
fret
peptid
deriv
cleavag
site
fret
peptid
fluoresc
quench
upon
cleavag
two
separ
fragment
hcv
proteas
fluoresc
recov
monitor
nm
excitationemiss
control
includ
buffer
compound
compound
fret
peptid
separ
test
well
control
repeat
triplic
plate
molecular
model
perform
hp
omenx
pc
processor
cpu
ghz
instal
memori
ram
ghz
oper
system
window
enterpris
enterpris
linux
distribut
molecular
comput
work
perform
use
suit
new
york
ny
usa
nonfus
protein
crystal
structur
pdb
code
download
protein
data
bank
websit
rcsborg
protein
prepar
accord
standard
procedur
protein
prepar
modul
maestro
briefli
first
stage
includ
preprocess
follow
simplif
protein
monom
remov
unus
ligand
water
final
energi
minim
perform
use
forc
field
moc
compound
sketch
use
acdchemsketch
freewar
advanc
chemistri
develop
inc
toronto
canada
save
sdf
file
import
maestro
ligand
optim
use
ligprep
standard
procedur
embed
maestro
suit
ligand
select
molecular
dynam
merg
visual
guidanc
onto
prepar
protein
remov
cocrystal
peptid
form
complex
enter
next
step
use
desmond
system
builder
modul
complex
prepar
md
simul
appli
molecular
mechan
forc
field
solvat
water
box
shape
orthorhomb
size
calcul
method
buffer
distanc
protein
box
volum
minim
volum
contain
nacl
ad
ion
paramet
use
default
system
builder
result
solvat
complex
subject
desmond
molecular
dynam
simul
set
follow
paramet
simul
time
ns
record
intern
trajectori
ps
approxim
number
frame
ensembl
class
normal
pressur
temperatur
npt
temperatur
k
pressur
bar
start
md
job
system
allow
relax
use
default
relax
protocol
paramet
use
default
elarabi
e
omar
elfaki
soror
h
khayat
asfour
h
z
baman
f
h
imidazolebas
compound
hepat
c
viru
inhibitor
us
applic
april
